

美時公告 4 月自結合併營收近新台幣 8 億元，較去年同期增加逾 34%，並創今年新高

*Lotus Reported Unaudited April Revenues of NT\$790 Million, a 34% Increase YoY and a record high YTD'20*

2020 年 5 月 10 日，台北

May 10<sup>th</sup>, 2020, Taipei

特殊學名藥廠美時化學製藥（以下簡稱“美時”，台灣證券交易所股票代碼：1795）公佈 2020 年 4 月自結合併營收達新台幣 790,366 仟元，較去年同期大幅成長逾三成、並創下今年以來營收新高。美時表示受惠於戒癮用藥 Buprenorphine/Naloxone 舌下含片客戶之美國市場份額不斷成長、拉貨狀況亦穩定增加，此外，癌症用藥之外銷出貨持續暢旺，使得整體外銷市場業務表現強勁；亞太區域業務亦因疫情減緩而逐漸回溫。

*Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that its consolidated sales for April 2020 was NT\$790,366 thousand, representing a 34% increase over the same period last year and the highest monthly sales number YTD'20. The outstanding performance is mainly driven by the stably increasing shipments of Buprenorphine/Naloxone film with continuously expanded market share in the US market and the sustainable supply revenue from export oncology portfolio. The Asian market business is also getting stabilized with gradually mitigated COVID-19 situation in Asia.*

**新聞聯繫人 Contact:**

美時製藥 投資人關係處長 樂君儀 (02)2700 5908 investor@lotuspharm.com

**Angela Luan, Investor Relations Director**

**關於美時：**

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，為一以台灣為基地供應全球市場之學名藥廠，高價值產品線涵蓋中樞神經系統、心血管疾病、癌症、女性保健、減肥等，並以錠劑、膠囊及軟膠囊劑型為主；美時自 2014 年成為艾威群集團的一員，現專注於快速成長的抗癌市場，並矢志透過整合台灣與韓國首屈一指的研發平台與其製造優勢嘉惠病患、員工與股東。美時的行銷與業務通路包含直營的亞洲市場及艾威群集團橫跨全球超過 30 個國家的商業網絡，此外，美時亦積極與一線藥廠就產品線策略結盟，是少數能進軍所有市場的新興藥廠。

**About Lotus**

*Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.*

聲明：

本文件及同時發佈之相關資訊內含有預測性敘述。除針對已發生事實，所有對美時製藥(以下簡稱本公司)未來經營業務、可能發生之事件及展望(包括但不限於預測、目標、估算和營運計劃)之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性的影響，造成與實際情況有相當差異，這些因素包括但不限於價格波動、實際需求、匯率變動、市占率、市場競爭情況，法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等，及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估，本公司不負日後更新之責。